Sanofi Wins Second Test Trial in Taxotere Cancer Drug Litigation

Nov. 22, 2021, 9:31 PM UTC

Sanofi-Aventis U.S. LLC and Sanofi US Services Inc. were again cleared of liability in litigation linking the breast cancer drug Taxotere to permanent hair loss, according to a judgment entered Monday in a Louisiana federal court.

Elizabeth Kahn alleged the drugmaker didn’t adequately warn that hair loss, a common side effect of chemotherapy, could be permanent.

Her suit was the second test trial and the second defense win in a multidistrict proceeding in the U.S. District Court for the Eastern District of Louisiana by women alleging they would have chosen a less toxic drug had they known the likelihood of ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.